

# CPX-351 in secondary/high-risk acute myeloid leukemia: a meta-analysis of randomized and real-world studies encompassing more than 3,200 patients

## Authors

---

Matteo Molica,<sup>1</sup> Diana Giannarelli,<sup>2</sup> Laura De Fazio,<sup>1</sup> Marco Rossi<sup>1</sup> and Salvatore Perrone<sup>3</sup>

<sup>1</sup>Department of Hematology-Oncology, Azienda Universitaria Ospedaliera Renato Dulbecco, Catanzaro; <sup>2</sup>Biostatistical Unit, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome and <sup>3</sup>Department of Hematology, S. M. Goretti Hospital, Polo Universitario Pontino, Latina, Italy

Correspondence:

M. MOLICA - molica@bce.uniroma1.it

<https://doi.org/10.3324/haematol.2025.300076>

Received: October 21, 2025.

Accepted: December 4, 2025.

Early view: December 11, 2025.

©2026 Ferrata Storti Foundation

Published under a CC BY-NC license 

**CPX-351 in Secondary/High-Risk AML: a Meta-analysis of Randomized and Real-World Studies Encompassing More Than 3200 Patients**


**SUPPLEMENTAL Material**

### List of the RWE studies cited in this meta-analysis

1. Mehta P, Campbell V, Maddox J, et al. CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK. *British Journal of Haematology*. 2024;205(4):1326-1336. doi:10.1111/bjh.19622
2. Rautenberg C, Stölzel F, Röllig C, et al. Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. *Blood Cancer J*. 2021;11(10):164. doi:10.1038/s41408-021-00558-5
3. Rautenberg C, Middeke JM, Röllig C, et al. Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patients. *Blood Cancer J*. 2025;15(1):60. doi:10.1038/s41408-025-01274-0
4. Legg A, Lambova A, Broe A, Levy J, Medalla G. Real-World Experience With CPX-351 Treatment for Acute Myeloid Leukemia in England: An Analysis From the National Cancer Registration and Analysis Service. *Clinical Lymphoma Myeloma and Leukemia*. 2023;23(10):e323-e330. doi:10.1016/j.clml.2023.07.003
5. Bernal T, Moreno AF, de LaIglesia A, et al. Clinical outcomes after CPX-351 in patients with high-risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry. *Cancer Med*. 2023;12(14):14892-14901. doi:10.1002/cam4.6120
6. Rodríguez-Arbolí E, Rodríguez-Veiga R, Soria-Saldise E, et al. A phase 2, multicenter, clinical trial of CPX-351 in older patients with secondary or high-risk acute myeloid leukemia: PETHEMA-LAMVYX. *Cancer*. 2025;131(1):e35618. doi:10.1002/cncr.35618
7. Peters DT, Nicolet D, Madanat YF, et al. Real-World Analysis of CPX-351 Induction in Acute Myeloid Leukemia-Myelodysplasia Related (AML-MR): An Updated Analysis from the Marrow Consortium. *Blood*. 2024;144(Supplement 1):324. doi:10.1182/blood-2024-193667
8. LeBlanc TW, Lai C, Ali A, et al. V-RULES: Real-world effectiveness and safety of CPX-351 in patients with secondary acute myeloid leukemia (AML). *J Clin Oncol*. 2025;43(16\_suppl):6520-6520. doi:10.1200/JCO.2025.43.16\_suppl.6520
9. Matthews AH, Perl AE, Luger SM, et al. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. *Blood Advances*. 2022;6(13):3997-4005. doi:10.1182/bloodadvances.2022007265
10. Guolo F, Fianchi L, Martelli MP, et al. Real World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation. *Am J Hematol*. Published online September 24, 2025. doi:10.1002/ajh.70083
11. Guolo F, Fianchi L, Minetto P, et al. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program. *Blood Cancer J*. 2020;10(10):96. doi:10.1038/s41408-020-00361-8

12. Chiche E, Rahmé R, Bertoli S, et al. Real-life experience with CPX-351 and impact on the outcome of high-risk AML patients: a multicentric French cohort. *Blood Advances*. 2021;5(1):176-184. doi:10.1182/bloodadvances.2020003159
13. Lee D, Jain AG, Deutsch Y, et al. CPX-351 Yields Similar Response and Survival Outcome in Younger and Older Patients With Secondary Acute Myeloid Leukemia. *Clin Lymphoma Myeloma Leuk*. 2022;22(10):774-779. doi:10.1016/j.clml.2022.06.001
14. Fernández Villalobos MJ, Ortiz J, Figuera Alvarez A, et al. Upfront CPX-351 Induction at 8 Spanish Hospital. Efficacy of CPX-351 in Everyday Clinical Practice and Increased Insight into Its Use in Younger Adults. *Blood*. 2024;144(Supplement 1):6034. doi:10.1182/blood-2024-202036
15. Lambova A, Ralphs, Eleanor, Keapoletswe, Karabo, Wester, Gry, Legg A. LONG-TERM REAL-WORLD EXPERIENCE WITH CPX-351 TREATMENT FOR ACUTE MYELOID LEUKEMIA IN ENGLAND. *HemaSphere*. 2025;9(S1):e294-5. doi:10.1002/hem3.70152

## Supplemental Figure 1. PRISMA diagram



**Supplemental Figure 2.** Forest plot of the 60-days mortality in patients from the included studies in this meta-analysis. The forest plot shows broader dispersion at 60 days, with some studies above and below the pooled line, but the combined RWE estimate trends modestly lower than RCTs.

